JAZZ - Jazz Pharmaceuticals plc
NASDAQ
->
Healthcare
->
Biotechnology
Dublin,
Ireland
Type: Equity
JAZZ price evolution
JAZZ
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $797.58 | $1355.8 | $1443.38 | $1506.31 |
| Short term investments | $625 | $375 | $120 | |
| Net receivables | $723.64 | $698.04 | $707.1 | $705.79 |
| Inventory | $539.3 | $542.55 | $577.32 | $597.04 |
| Total current assets | $4390.42 | $3681.67 | $3539.9 | $3435.43 |
| Long term investments | ||||
| Property, plant & equipment | $253.59 | $242.43 | $227.87 | $234.99 |
| Goodwill & intangible assets | $6815.39 | $6974.99 | $7171.17 | |
| Total noncurrent assets | $7680.2 | $7787.18 | $7957.93 | |
| Total investments | $625 | $375 | $120 | |
| Total assets | $12255.72 | $11361.87 | $11327.08 | $11393.36 |
| Current liabilities | ||||
| Accounts payable | $85.42 | $97.1 | $80.98 | $102.75 |
| Deferred revenue | ||||
| Short long term debt | $605.8 | $605.38 | $604.95 | |
| Total current liabilities | $1029.98 | $1556.03 | $1562.21 | $1536.69 |
| Long term debt | $6080.8 | $5168.6 | $5161.27 | $5167.21 |
| Total noncurrent liabilities | $6043.24 | $6068.41 | $6119.67 | |
| Total debt | $5774.4 | $5766.64 | $5772.17 | |
| Total liabilities | $8084.65 | $7599.27 | $7630.61 | $7656.36 |
| Shareholders' equity | ||||
| Retained earnings | $936.71 | $871.18 | $864.04 | $878.66 |
| Other shareholder equity | -$603.4 | -$888.23 | -$882.39 | -$842.15 |
| Total shareholder equity | $3762.6 | $3696.46 | $3737 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1506.31 | $334.02 | $591.45 | $1057.77 |
| Short term investments | $120 | $1075 | ||
| Net receivables | $705.79 | $742.63 | $563.36 | $396.49 |
| Inventory | $597.04 | $714.06 | $1072.72 | $95.4 |
| Total current assets | $3435.43 | $2606.14 | $2611.33 | $2839.57 |
| Long term investments | ||||
| Property, plant & equipment | $234.99 | $301.38 | $343.42 | $257.1 |
| Goodwill & intangible assets | $7171.17 | $7487.1 | $8979.94 | $3153.35 |
| Total noncurrent assets | $7957.93 | $8229.11 | $9687.31 | $3696.33 |
| Total investments | $120 | $1075 | ||
| Total assets | $11393.36 | $10835.25 | $12298.64 | $6535.9 |
| Current liabilities | ||||
| Accounts payable | $102.75 | $90.76 | $100.3 | $26.95 |
| Deferred revenue | $0.46 | $2.56 | $4.86 | |
| Short long term debt | $604.95 | $31 | $31 | $246.32 |
| Total current liabilities | $1536.69 | $933.19 | $809.3 | $653.75 |
| Long term debt | $5167.21 | $5698.55 | $6106.14 | $1988.55 |
| Total noncurrent liabilities | $6119.67 | $6816.33 | $7524.15 | $2222.41 |
| Total debt | $5772.17 | $5796.18 | $6137.14 | $2234.87 |
| Total liabilities | $7656.36 | $7749.52 | $8333.45 | $2876.16 |
| Shareholders' equity | ||||
| Retained earnings | $878.66 | $734.06 | $830.23 | $1159.89 |
| Other shareholder equity | -$842.15 | -$1125.51 | -$400.36 | -$134.35 |
| Total shareholder equity | $3737 | $3085.73 | $3965.19 | $3659.74 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1054.97 | $1023.83 | $901.98 | $1011.93 |
| Cost of revenue | $109.9 | $95.49 | $107.24 | |
| Gross Profit | $943.36 | $913.92 | $806.5 | $904.69 |
| Operating activities | ||||
| Research & development | $220.73 | $222.85 | $216.61 | |
| Selling, general & administrative | $338.52 | $351.71 | $396.03 | |
| Total operating expenses | $683.15 | $714.48 | $740.29 | $782.2 |
| Operating income | $199.44 | $66.21 | $122.5 | |
| Income from continuing operations | ||||
| EBIT | $199.94 | $63.17 | $131.39 | |
| Income tax expense | -$14.53 | -$30.65 | $11.67 | -$33.09 |
| Interest expense | -$59.4 | $62.02 | $66.12 | $70.32 |
| Net income | ||||
| Net income | $215.06 | $168.57 | -$14.62 | $94.15 |
| Income (for common shares) | $168.57 | -$14.62 | $94.15 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3834.2 | $3659.37 | $3094.24 | $2363.57 |
| Cost of revenue | $435.58 | $540.52 | $440.76 | $148.92 |
| Gross Profit | $3398.63 | $3118.86 | $2653.48 | $2214.65 |
| Operating activities | ||||
| Research & development | $849.66 | $590.45 | $505.75 | $335.38 |
| Selling, general & administrative | $1343.11 | $1416.97 | $1451.68 | $854.23 |
| Total operating expenses | $2820.05 | $3184.39 | $2483.2 | $1836.58 |
| Operating income | $578.58 | -$65.53 | $170.28 | $378.07 |
| Income from continuing operations | ||||
| EBIT | $584.36 | -$94.46 | $165.21 | $371.84 |
| Income tax expense | -$119.91 | -$158.65 | $216.12 | $33.52 |
| Interest expense | $289.44 | $288.24 | $278.77 | $99.71 |
| Net income | ||||
| Net income | $414.83 | -$224.06 | -$329.67 | $238.62 |
| Income (for common shares) | $414.83 | -$224.06 | -$329.67 | $238.62 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $168.57 | -$14.62 | $94.15 | |
| Operating activities | ||||
| Depreciation | $163.03 | $163.38 | $159.2 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $56.65 | $61.44 | $52.94 | |
| Total cash flows from operations | $331.35 | $267.23 | $167.34 | |
| Investing activities | ||||
| Capital expenditures | -$7.09 | -$6.9 | -$10.1 | |
| Investments | -$250 | -$255 | $129.9 | |
| Total cash flows from investing | -$314.91 | -$257.09 | -$271.9 | $101.8 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$164.28 | -$49.3 | -$101.41 | |
| Net borrowings | -$7.75 | -$7.75 | -$7.75 | |
| Total cash flows from financing | $28.79 | -$161.09 | -$56.55 | -$100.31 |
| Effect of exchange rate | $0.61 | -$0.76 | -$1.7 | $1.79 |
| Change in cash and equivalents | $711.83 | -$87.58 | -$62.92 | $170.62 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $414.83 | -$224.06 | -$329.67 | $238.62 |
| Operating activities | ||||
| Depreciation | $638.7 | $629.47 | $552.48 | $278.25 |
| Business acquisitions & disposals | $53 | -$6234.79 | ||
| Stock-based compensation | $226.84 | $222 | $189.01 | $121 |
| Total cash flows from operations | $1092.01 | $1271.98 | $778.51 | $899.65 |
| Investing activities | ||||
| Capital expenditures | -$23.96 | -$29.05 | -$27.64 | -$0.74 |
| Investments | -$120.1 | -$1.04 | $1068.18 | -$642.67 |
| Total cash flows from investing | -$163.06 | -$446.23 | -$5212.14 | -$1007.67 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$320.71 | -$45.5 | -$35.6 | -$163.41 |
| Net borrowings | -$31 | -$582.01 | $3870.86 | $591.81 |
| Total cash flows from financing | -$305.25 | -$529.49 | $3970.52 | $528.07 |
| Effect of exchange rate | $1.14 | -$6.22 | -$3.21 | $0.37 |
| Change in cash and equivalents | $624.83 | $290.03 | -$466.32 | $420.43 |
News
Fundamentals
| Market cap | $7.43B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 60.44M |
| Revenue | $3.99B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $463.16M |
| Revenue Q/Q | 8.52% |
| Revenue Y/Y | 5.23% |
| P/E ratio | 16.05 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.86 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 13.20 |
| EPS | $7.66 |
|---|---|
| ROA | 4.00% |
| ROE | N/A |
| Debt/Equity | 2.05 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.26 |
| Quick ratio | 3.74 |